Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Studies on antitumor actions of cantharidin.

× No keyword cloud information.

6 in total

1. Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.

Authors: C Liu; B F Kimler; R G Evans; R A Morantz
Journal: J Neurooncol Date: 1993-02 Impact factor: 4.130

Review 2. Anticancer Attributes of Cantharidin: Involved Molecular Mechanisms and Pathways.

Authors: Faiza Naz; Yixin Wu; Nan Zhang; Zhao Yang; Changyuan Yu
Journal: Molecules Date: 2020-07-19 Impact factor: 4.411

3. Breaking Glucose Transporter 1/Pyruvate Kinase M2 Glycolytic Loop Is Required for Cantharidin Inhibition of Metastasis in Highly Metastatic Breast Cancer.

Authors: Yanhong Pan; Qian Zheng; Wenting Ni; Zhonghong Wei; Suyun Yu; Qi Jia; Meng Wang; Aiyun Wang; Wenxing Chen; Yin Lu
Journal: Front Pharmacol Date: 2019-05-24 Impact factor: 5.810

4. N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production.

Authors: Ming-Che Chang; Jin-Yi Wu; Hui-Fen Liao; Yu-Jen Chen; Cheng-Deng Kuo
Journal: Anticancer Drugs Date: 2015-11 Impact factor: 2.248

5. Comparative assessment of therapeutic safety of norcantharidin, N-farnesyloxy-norcantharimide, and N-farnesyl-norcantharimide against Jurkat T cells relative to human normal lymphoblast: A quantitative pilot study.

Authors: Ming-Che Chang; Jin-Yi Wu; Hui-Fen Liao; Yu-Jen Chen; Cheng-Deng Kuo
Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889

6. Pharmacological mechanism of mylabris in the treatment of leukemia based on bioinformatics and systematic pharmacology.

Authors: Huali Zhan; Yujiao Bai; Yu Lv; Xianqin Zhang; Lin Zhang; Shanshan Deng
Journal: Bioengineered Date: 2021-12 Impact factor: 3.269

6 in total